Reassessment for radical surgery after palliative chemotherapy in locally advanced pancreatic carcinoma: Two case-reports

Lideståhl, Anders; Permert, Johan; Linder, Stefan; Bylund, Håkan; Edsborg, Nick; Lind, Pehr

doi:10.1080/02841860500537572

Cited by 1 publication

(1 citation statement)

References 8 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As showed in this article, gemcitabine-based combination chemotherapy has generally proven disappointing in terms of clinically significantly better outcome in overall survival compared to gemcitabine only. However, as shown in the case reports, described by us, in a Letter to the Editor section in this issue, individual patients can benefit well from combination chemotherapy and even be reassessed for radical surgery [45].…”

Section: Discussionmentioning

confidence: 92%

Efficacy of systemic therapy in advanced pancreatic carcinoma

Lideståhl¹,

Permert²,

Linder³

et al. 2006

Acta Oncologica

Self Cite

View full text Add to dashboard Cite

With a worldwide incidence of more than 200,000 cases and almost as many deaths, pancreatic carcinoma (PC) remains one of the leading causes of cancer deaths, especially in the Western world. Due to the late onset of symptoms, almost all patients suffer from disseminated disease at the time of diagnosis and only a minority will ever be candidates for radical surgery. Only about one tenth of the operated patients remain disease free. For these reasons, development of effective palliative systemic therapy is important. Almost a decade ago, gemcitabine replaced 5-Fu as the gold standard in systemic treatment of advanced PC. Since then, a number of trials have investigated the potential additional effect of several cytotoxic or targeted agents in combination with gemcitabine. As shown in this review, nearly all these trials have proved disappointing. This review provides an overview of the results of current phase III trials of gemcitabine based systemic therapy. Furthermore, we discuss the role of systemic therapy compared to BSC only and the potential future role of targeted therapies.

show abstract

Section: Discussionmentioning

confidence: 92%